Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

Who May Qualify: - Primary diagnosis of BED according to DSM-5 criteria. - Provides written willing to sign a consent form to participate in the study before the conduct of any study procedures. - Male or female, aged 18 to 55 inclusive. Who Should NOT Join This Trial: - Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription. - Unable to comply with study procedures. - Medically inappropriate for study participation in the opinion of the investigator. Always talk to your doctor about whether this trial is right for you.